Sugi Predict

Sugi Predict / Compounds / SCHEMBL15470920

SCHEMBL15470920

SCHEMBL15470920

CC(=O)c1c(F)c(F)c(NCc2ccccc2)c(F)c1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.55
▸ CA13 Q8N1Q1 2/20 0.55
▸ CA1 P00915 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ TSHR P16473 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ LMNA P02545 3/20 0.43
▸ RAD52 P43351 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ASPH Q12797 1/20 0.42
▸ KDM8 Q8N371 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21371036 0.87 CA2 (0.58) CA2CA13CA1CA12CA7
SCHEMBL4404451 0.84 TSHR (0.56) CA2CA13CA1CA12CA7
SCHEMBL29950022 0.80 CA2 (0.66) CA2CA13CA1CA12CA7
SCHEMBL4405351 0.76 CYP2C9 (0.49) CA2CA13CA1CA12CA7
SCHEMBL4406810 0.75 CA1 (0.50) CA2CA13CA1CA12CA7
SCHEMBL19478138 0.75 CA2 (0.50) CA2CA13CA1CA12CA7
SCHEMBL16589426 0.72 NPSR1 (0.51) TSHRALDH1A1MAPK1LMNAMAPT
SCHEMBL9501324 0.72 TSHR (0.46) CA2CA13CA1CA12CA7
SCHEMBL19478209 0.72 CA2 (0.47) CA2CA13CA1CA12CA7
SCHEMBL6533513 0.72 ALDH1A1 (0.44) ALDH1A1USP2ALOX15MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745311-B2 Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors INCYTE CORPORATION (US) 2017-08-29 — — US disclosed
US-20160280713-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS INCYTE CORPORATION 2016-09-29 — — US disclosed
US-9388185-B2 Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-07-12 — — US disclosed
US-9266892-B2 Fused pyrazoles as FGFR inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-02-23 — — US disclosed
US-20140171405-A1 Fused Pyrazoles as FGFR Inhibitors INCYTE CORPORATION (US) 2014-06-19 — — US disclosed
US-20140045814-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171405-A1 Fused Pyrazoles as FGFR Inhibitors FGFR1, FGFR3, FGFR2 CA2 3612/4885CA13 4156/4885CA1 4658/4885
US-20160280713-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS FGFR1, FGFR2, FGFR3 CA2 3356/4885CA13 4566/4885CA1 4758/4885
US-20140045814-A1 PYRAZINE DERIVATIVES AS FGFR INHIBITORS FGFR1, FGFR2, FGFR3 CA2 3356/4885CA13 4566/4885CA1 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.